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Cancer biology: Extracellular proteinases in malignancy
Lynn M. Matrisian
Secreted, matrix-degrading proteinases have been
viewed as contributing to tumor metastasis. A recent
study indicates that the gene for one of these enzymes,
the matrix metalloproteinase stromelysin-1, can actually
cause cancer when expressed in transgenic mice. 
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Tumors generally progress through a series of defined
steps. A normal cell can become aberrant in the pathways
that regulate its growth and death, resulting in a benign,
well-circumscribed tumor. Conversion to malignancy
occurs when the cells gain the ability to invade into the
surrounding tissue. Malignant cells can metastasize,
establishing colonies at distant sites and threatening the
life of the host. The tumorigenic process is initiated by
mutations in key regulatory genes, either gain-of-function
mutations that generate oncogenes or loss-of-function
mutations in tumor suppressor genes. Ultimately, gene
expression patterns can be altered as a consequence of
these mutations, resulting in changes in cellular pheno-
type. For example, the process of invasion involves
changes in the expression of genes encoding molecules
involved in cell adhesion and migration, and in the elabo-
ration of proteinases that degrade the matrix barriers sur-
rounding the tumor. Interactions with the vasculature and
the immune system are altered as a consequence of some
of these phenotypic differences. Understanding carcino-
genesis at the molecular level requires an appreciation of
both the genetic and the epigenetic events that contribute
to tumor progression.
The matrix metalloproteinase family of zinc-dependent,
extracellular proteinases are recognized as targets of
oncogenic signal transduction pathways that contribute to
the malignant phenotype [1]. Several members of the
matrix metalloproteinase family were initially identified as
the proteins encoded by oncogene-inducible or tumor-
specific transcripts, and the matrix metalloproteinase
genes contain elements that are highly responsive to
oncogenic transcription factors. The protein products are
secreted into the extracellular environment where they
degrade the proteins, glycoproteins and proteoglycans of
the basement membrane and extracellular matrix that
form the structural scaffold of tissues. The contribution of
these enzymes to tumor invasion and metastasis has been
demonstrated repeatedly by studies with both the natural
tissue inhibitors of metalloproteinases (TIMPs), as well as
with newer synthetic matrix metalloproteinase inhibitors
[1,2]. The involvement of matrix metalloproteinases in
late stages of tumor invasion and metastasis has thus been
well-established.
A recent study by Sternlicht et al. [3] has given a very
different picture of the role played by a secreted pro-
teinase in malignancy. They found that overproduction of
the matrix metalloproteinase stromelysin-1 in the
mammary gland of transgenic mice caused changes
encompassing all stages of tumor progression, ranging
from hyperplasia to malignant carcinomas. In an extensive
study, involving 163 mice with a median age of 18 months
from five independent transgenic lines, 64% had hyper-
plasia, 20% had atypical proliferative lesions (dysplasia) or
carcinoma in situ, and 7.4% developed mammary carcino-
mas. Of the nine carcinomas that developed, three
showed evidence of being highly advanced and one
metastasized to the lung and kidney. These results are
reminiscent of classic experiments that used a transgenic
approach to certify genes found mutated in cancer as
oncogenes. For example, the results of expressing the H-
ras, myc, int/wnt-1 and neu oncogenes under the control of
a mammary-specific promoter confirmed their central role
in carcinogenesis [4]. Does this mean that the genes
Figure 1
Stromelysin-1 expression in a malignant tumor. Stromelysin-1 mRNA
(red color) was detected by in situ hybridization in the stroma of a
malignant squamous cell carcinoma that had been induced by
treatment of mouse skin with a chemical initiator followed by repeated
treatment with the tumor promoter TPA [10].
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encoding stromelysin-1, and potentially those encoding
other matrix-degrading proteinases, can be oncogenes?
Before assessing if a matrix metalloproteinase can be an
oncogene product, the normal expression pattern of
stromelysin-1 should be considered. Stromelysin-1, like
most matrix metalloproteinases, is not usually expressed by
the malignant tumor cells themselves, but instead is pro-
duced by the normal connective tissue (stromal) cells sur-
rounding the tumor as part of the ‘host’ response to the
tumor. The common adult cancers, such as breast, colon
and prostate cancer, are adenocarcinomas which arise as a
result of mutations in the epithelial cells that line the
ductal structures in these organs. It seems that the normal
cells surrounding the tumor view these changes as a wound
and attempt to heal it. Inflammatory cells appear on the
scene, and the fibroblasts that reside in the connective
tissue surrounding the tumor become reactive. Secreted
proteinases, including stromelysin-1, are produced by these
fibroblasts and inflammatory cells, presumably as part of
that reaction (Figure 1). The stroma becomes an integral
part of the tumor, and there is an increasing appreciation of
the contribution these non-malignant cells make to the
tumor progression process.
The finding that stromelysin-1 behaves like the product
of an oncogene is surprising for several reasons. Secreted
proteases have been viewed as effectors of invasion and
metastasis, and as such should not play a causal role in
the earliest stages of tumor progression. An effect on the
initiation of tumorigenesis is even more surprising if it is
caused by an enzyme that is usually produced by normal
stromal cells. The data, however, are unequivocal.
Sternlicht et al. [3] used several approaches to confirm
their results. Mammary carcinomas were observed in mice
from three different founders, and two sublines of
stromelysin-1 transgenic mice showed reversal of the
phenotype that correlated with silencing of transgene
expression. And when the stromelysin-1 transgene was
crossed onto a background in which TIMP-1 was
produced under the control of the same mammary-spe-
cific promoter, there was a reduction in the number of
mice with mammary hyperplasia — a surrogate endpoint
of tumorigenesis — from 73% to 19%. These results indi-
cate that stromelysin-1 proteolytic activity was required
for the observed effect. 
As an additional test, murine mammary epithelial cells in
which stromelysin-1 was expressed under the control of a
tetracycline-repressible promoter were injected into the
mammary fat pad of immunocompromised mice. Tetra-
cycline-treated mice developed relatively normal ducts
and glandular-like structures. Mice in which stromelysin-1
expression was induced by withholding tetracycline from
the drinking water developed small tumors in 28% of the
injected sites. If stromelysin-1 expression was induced in
culture for two months prior to injection, 100% of the
injection sites developed tumors, irrespective of the
presence or absence of tetracycline in the drinking water.
This suggests that the changes initiated by stromelysin-1
expression are stable and do not require continuous
exposure to the enzyme.
Although stromelysin-1 expression was targeted to
epithelial cells in these studies [3], it is likely that its
expression in stromal cells would have the same result.
Studies with the related stromally expressed matrix metal-
loproteinase, stromelysin-3, have indicated a pro-tumori-
genic effect of this enzyme in mammary cancer, whether it
is produced by the tumor or stromal cells. Transfected
human breast cancer cells expressing stromelysin-3 were
found to be more tumorigenic than controls when injected
subcutaneously into immunocompromised mice [5].
Similarly, the tumorigenicity of breast cancer cells was
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Figure 2
Normal epithelial cells can become initiated
by exposure to agents that cause mutations
in critical oncogenes or tumor suppressor
genes. Repeated exposure to a tumor
promoter can result in the development of
benign tumors, which are often initially
dependent on the continued treatment with
the tumor promoter but can progress to
become autonomous. Further genetic
changes result in the conversion to a
malignant tumor, characterized by the loss of
an intact basement membrane. Tumor cells
can become invasive and penetrate into
underlying connective tissue. This connective
tissue, composed of extracellular matrix,
fibroblasts (blue), inflammatory cells (red),
and blood vessels (tubular structures), also
becomes an integral part of the tumor (grey
finger-like projections). The tumor cells can
circulate through lymphatic and blood
vessels, invade through the vessel walls, and
acquire the ability to establish a secondary
tumor at a distant site — the process known
as metastasis. The matrix metalloproteinase
stromelysin-1 has now been shown to act as
a tumor promoter in transgenic mice: in
genetically-susceptible mice, it can induce
the development of tumors at all stages of
tumor progression.
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enhanced when they were mixed with stromelysin-3-
expressing fibroblasts, compared to when mixed with
fibroblasts derived from stromelysin-3-null mice [6]. The
important substrate for the action of these enzymes is
therefore likely to be either part of the extracellular matrix
or on the cell surface, accessible to secreted proteinases
regardless of their site of synthesis.
How do we explain these properties of stromelysin-1? As
the authors indicate, matrix metalloproteinases are not
mutagens, and must therefore act by virtue of their ability
to affect cellular signaling. Considerable insights into the
carcinogenic process have been gained from studies with
chemical carcinogens. In the two-step model of carcino-
genesis (Figure 2), tumors are induced by a single applica-
tion of a tumor initiator — a mutagen — followed by
repeated application of a tumor promoter [7]. Tumor pro-
moters, such as the phorbol ester TPA, are not mutagenic
and have as one of their characteristics the ability to
induce cellular proliferation, although not all growth-
inducing factors have tumor promoting activity. These
compounds ‘fix’ the mutations caused by the initiator so
that they are passed on to subsequent cell generations. If
the mutation is in a gene that provides a growth advantage
to the cell, these cells eventually dominate the population
and result in a benign tumor. The benign tumors can
become autonomous, no longer requiring continual expo-
sure to the tumor promoter. Further mutations cause the
conversion of the benign tumor to malignancy. Tumor
development can be enhanced by genes that act as either
tumor initiators or tumor promoters, as long as the other
function is present.
Stromelysin-1 appears to act as a tumor promoter in
mammary carcinogenesis. This would suggest that the
immortal mammary cell line used in these studies is
‘initiated’, and that the transgenic mice also undergo a low,
spontaneous rate of initiation. Interestingly, the effects of
stromelysin-1 expression depended on the genetic back-
ground. Tumors did not develop on an FVB background as
they did on the CD1 genetic background (Z. Werb, per-
sonal communication). And expression of stromelysin-1
under the control of a different mammary-specific promoter
did not induce tumors in DBA/C57Bl6 mice [8], as it has
been shown to do on a CD1 background (M. Henderson
and L. Matrisian, unpublished observation). Susceptibility
to multistage carcinogenesis protocols is also highly depen-
dent on genetic background [9]. These results would be
consistent with stromelysin-1 acting as a tumor promoter in
mice that are genetically prone to events that initiate
mammary carcinogenesis.
The demonstration that stromelysin-1 acts as a tumor
promoter for mammary carcinogenesis [3] has increased
our appreciation of the role the extracellular environment
plays in cancer. The considerable advances over the past
decade in the field of cancer genetics have tended to
emphasise those genes whose function is critical to
maintaining cellular homeostasis. Mutations in these genes
can initiate cancer. But an initiated cell is not a threat to
the health of the host unless it is promoted and then con-
verted to malignancy. It is becoming increasingly clear that
communication between the initiated cell and its environ-
ment contributes to this process. It might prove possible to
use inhibitors of matrix metalloproteinases — which are
currently in clinical trials as anti-metastasis and anti-angio-
genesis agents — to disrupt interactions between the
tumor and its reactive stroma at any stage of tumor pro-
gression. One of the most exciting implications of this
work is the possibility that matrix metalloproteinase
inhibitors might be useful in reducing or preventing malig-
nancy in high-risk populations.
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